{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T13:14:43Z","timestamp":1789132483920,"version":"build-2803163510"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,20]],"date-time":"2025-12-20T00:00:00Z","timestamp":1766188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T00:00:00Z","timestamp":1769126400000},"content-version":"vor","delay-in-days":34,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"DOI":"10.1186\/s13075-025-03710-9","type":"journal-article","created":{"date-parts":[[2025,12,20]],"date-time":"2025-12-20T06:26:27Z","timestamp":1766211987000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Baricitinib ameliorates skin fibrosis via direct fibroblast suppression and endothelial exosome-mediated paracrine signaling"],"prefix":"10.1186","volume":"28","author":[{"given":"Zhanying","family":"Hou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiufeng","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shi","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,20]]},"reference":[{"issue":"10373","key":"3710_CR1","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1016\/S0140-6736(22)01692-0","volume":"401","author":"ER Volkmann","year":"2023","unstructured":"Volkmann ER, Andr\u00e9asson K, Smith V. Systemic Scler Lancet. 2023;401(10373):304\u201318.","journal-title":"Systemic Scler Lancet"},{"issue":"3","key":"3710_CR2","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1007\/s12016-021-08889-8","volume":"64","author":"ME Truchetet","year":"2023","unstructured":"Truchetet ME, Brembilla NC, Chizzolini C. Current concepts on the pathogenesis of systemic sclerosis. Clin Rev Allergy Immunol. 2023;64(3):262\u201383.","journal-title":"Clin Rev Allergy Immunol"},{"key":"3710_CR3","doi-asserted-by":"publisher","first-page":"43","DOI":"10.12703\/r\/10-43","volume":"10","author":"JL Zhu","year":"2021","unstructured":"Zhu JL, et al. Emerging treatments for scleroderma\/systemic sclerosis. Fac Reviews. 2021;10:43.","journal-title":"Fac Reviews"},{"issue":"1","key":"3710_CR4","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1513\/AnnalsATS.202301-053OC","volume":"21","author":"H Barnes","year":"2024","unstructured":"Barnes H, et al. Cyclophosphamide in patients with systemic Sclerosis\u2013associated interstitial lung disease: A systematic review and Meta-Analysis. Annals Am Thorac Soc. 2024;21(1):122\u201335.","journal-title":"Annals Am Thorac Soc"},{"issue":"1","key":"3710_CR5","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1513\/AnnalsATS.202301-054OC","volume":"21","author":"D Herman","year":"2024","unstructured":"Herman D, et al. Mycophenolate in patients with systemic Sclerosis\u2013associated interstitial lung disease: A systematic review and Meta-Analysis. Annals Am Thorac Soc. 2024;21(1):136\u201350.","journal-title":"Annals Am Thorac Soc"},{"issue":"6","key":"3710_CR6","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1080\/13543784.2021.1923693","volume":"30","author":"A Lescoat","year":"2021","unstructured":"Lescoat A, et al. New promising drugs for the treatment of systemic sclerosis: pathogenic considerations, enhanced classifications, and personalized medicine. Expert Opin Investig Drugs. 2021;30(6):635\u201352.","journal-title":"Expert Opin Investig Drugs"},{"key":"3710_CR7","doi-asserted-by":"crossref","unstructured":"Bryon J, et al. Systemic sclerosis dermal fibroblast exosomes trigger type 1 interferon responses in keratinocytes via a TBK\/JAK\/STAT signaling axis. Arthritis & Rheumatology. 2025;77(3):322\u201334.","DOI":"10.1002\/art.43029"},{"issue":"1","key":"3710_CR8","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1186\/s13075-022-02787-w","volume":"24","author":"M Rokni","year":"2022","unstructured":"Rokni M, et al. The role of endothelin and RAS\/ERK signaling in immunopathogenesis-related fibrosis in patients with systemic sclerosis: an updated review with therapeutic implications. Arthritis Res Therapy. 2022;24(1):108.","journal-title":"Arthritis Res Therapy"},{"issue":"3","key":"3710_CR9","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.jdermsci.2025.02.001","volume":"117","author":"Q Luo","year":"2025","unstructured":"Luo Q, et al. The role and mechanism of JAK2 inhibitor in endothelial mesenchymal transition in systemic sclerosis. J Dermatol Sci. 2025;117(3):71\u201380.","journal-title":"J Dermatol Sci"},{"issue":"6","key":"3710_CR10","doi-asserted-by":"publisher","first-page":"2380","DOI":"10.3390\/ijms26062380","volume":"26","author":"E Grossini","year":"2025","unstructured":"Grossini E, et al. Characterization of Circulating vesicles of complicated and uncomplicated systemic sclerosis patients and their role in vascular dysfunction. Int J Mol Sci. 2025;26(6):2380.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"3710_CR11","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1186\/s12951-022-01636-x","volume":"20","author":"Y Lin","year":"2022","unstructured":"Lin Y, et al. Huc-MSC-derived exosomes modified with the targeting peptide of aHSCs for liver fibrosis therapy. J Nanobiotechnol. 2022;20(1):432.","journal-title":"J Nanobiotechnol"},{"issue":"4","key":"3710_CR12","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1080\/13543784.2023.2199919","volume":"32","author":"S Kubo","year":"2023","unstructured":"Kubo S, Nakayamada S, Tanaka Y. JAK inhibitors for rheumatoid arthritis. Expert Opin Investig Drugs. 2023;32(4):333\u201344.","journal-title":"Expert Opin Investig Drugs"},{"key":"3710_CR13","doi-asserted-by":"publisher","first-page":"859330","DOI":"10.3389\/fmed.2022.859330","volume":"9","author":"Z Hou","year":"2022","unstructured":"Hou Z, et al. JAK1\/2 inhibitor baricitinib improves skin fibrosis and digital ulcers in systemic sclerosis. Front Med. 2022;9:859330.","journal-title":"Front Med"},{"issue":"8","key":"3710_CR14","doi-asserted-by":"publisher","first-page":"936","DOI":"10.3390\/ph15080936","volume":"15","author":"P Kotyla","year":"2022","unstructured":"Kotyla P, et al. Jak inhibitors for treatment of autoimmune diseases: lessons from systemic sclerosis and systemic lupus erythematosus. Pharmaceuticals. 2022;15(8):936.","journal-title":"Pharmaceuticals"},{"issue":"11","key":"3710_CR15","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1007\/s004030000180","volume":"292","author":"T Yamamoto","year":"2000","unstructured":"Yamamoto T, Eckes B, Krieg T. Bleomycin increases steady-state levels of type I collagen, fibronectin and decorin mRNAs in human skin fibroblasts. Arch Dermatol Res. 2000;292(11):556\u201361.","journal-title":"Arch Dermatol Res"},{"issue":"1","key":"3710_CR16","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s42358-023-00325-z","volume":"63","author":"H Liu","year":"2023","unstructured":"Liu H, et al. Baricitinib improves pulmonary fibrosis in mice with rheumatoid arthritis-associated interstitial lung disease by inhibiting the Jak2\/Stat3 signaling pathway. Adv Rheumatol. 2023;63(1):45.","journal-title":"Adv Rheumatol"},{"issue":"1","key":"3710_CR17","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1177\/2397198319865367","volume":"5","author":"W Wang","year":"2020","unstructured":"Wang W, et al. The JAK\/STAT pathway is activated in systemic sclerosis and is effectively targeted by Tofacitinib. J Scleroderma Relat Disorders. 2020;5(1):40\u201350.","journal-title":"J Scleroderma Relat Disorders"},{"issue":"5","key":"3710_CR18","doi-asserted-by":"publisher","first-page":"e15164","DOI":"10.1111\/1756-185X.15164","volume":"27","author":"Y Wei","year":"2024","unstructured":"Wei Y, et al. JAK2 inhibitors improve RA combined with pulmonary fibrosis in rats by downregulating SMAD3 phosphorylation. Int J Rheum Dis. 2024;27(5):e15164.","journal-title":"Int J Rheum Dis"},{"key":"3710_CR19","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1136\/annrheumdis-2023-eular.5329","volume":"82","author":"S Gulle","year":"2023","unstructured":"Gulle S, et al. POS0628 BARICITINIB AMELIORATES BLEOMYCIN-INDUCED PULMONARY AND SKIN FIBROSIS VIA JAK 1\/2 INHIBITON. Ann Rheum Dis. 2023;82:588\u20139.","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"3710_CR20","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.3390\/cells8101276","volume":"8","author":"C Liu","year":"2019","unstructured":"Liu C, et al. Inhibition of JAK-STAT signaling with baricitinib reduces inflammation and improves cellular homeostasis in Progeria cells. Cells. 2019;8(10):1276.","journal-title":"Cells"},{"issue":"2","key":"3710_CR21","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1038\/onc.2017.338","volume":"37","author":"D Tarade","year":"2018","unstructured":"Tarade D, Ohh M. The HIF and other quandaries in VHL disease. Oncogene. 2018;37(2):139\u201347.","journal-title":"Oncogene"},{"key":"3710_CR22","unstructured":"Shabib S et al. JAK\/STAT is a main signaling pathway in renal carcinoma: a systematic review of therapeutic potential. J Inflamm Dis. 2025;29(1):e160171."},{"issue":"3","key":"3710_CR23","doi-asserted-by":"publisher","first-page":"195","DOI":"10.3109\/08916939908994064","volume":"31","author":"MB Kahalefp","year":"1999","unstructured":"Kahalefp MB, Leroy EC. Autoimmunity and vascular involvement in systemic sclerosis (SSc). Autoimmunity. 1999;31(3):195\u2013214.","journal-title":"Autoimmunity"},{"issue":"1","key":"3710_CR24","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1186\/s13075-025-03595-8","volume":"27","author":"S Piera-Velazquez","year":"2025","unstructured":"Piera-Velazquez S, et al. Identification of serum exosome proteins in systemic sclerosis with interstitial lung disease by aptamer proteomics. Arthritis Res Therapy. 2025;27(1):146.","journal-title":"Arthritis Res Therapy"},{"issue":"12","key":"3710_CR25","doi-asserted-by":"publisher","first-page":"2101","DOI":"10.3390\/life12122101","volume":"12","author":"E Fiorentini","year":"2022","unstructured":"Fiorentini E, et al. Potential role of JAK inhibitors in the treatment of systemic sclerosis-associated interstitial lung disease: a narrative review from pathogenesis to real-life data. Life. 2022;12(12):2101.","journal-title":"Life"},{"issue":"1","key":"3710_CR26","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.jdermsci.2016.04.006","volume":"83","author":"M Stenstr\u00f6m","year":"2016","unstructured":"Stenstr\u00f6m M, et al. Paquinimod reduces skin fibrosis in tight skin 1 mice, an experimental model of systemic sclerosis. J Dermatol Sci. 2016;83(1):52\u20139.","journal-title":"J Dermatol Sci"}],"container-title":["Arthritis Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13075-025-03710-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-025-03710-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-025-03710-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T13:07:52Z","timestamp":1769173672000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13075-025-03710-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,20]]},"references-count":26,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["3710"],"URL":"https:\/\/doi.org\/10.1186\/s13075-025-03710-9","relation":{},"ISSN":["1478-6362"],"issn-type":[{"value":"1478-6362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,20]]},"assertion":[{"value":"8 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"18"}}